Patents Assigned to Guilford Pharmaceuticals, Inc.
  • Patent number: 7479535
    Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: January 20, 2009
    Assignee: Guilford Pharmaceuticals, Inc.
    Inventors: Keith Branham, Mahesh V. Chaubal, James P. English, Donna Hall, Zhong Zhao
  • Patent number: 7220780
    Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 22, 2007
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Krystyna Wozniak
  • Patent number: 7148250
    Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALAdase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 12, 2006
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Brian Grella, Pavel Majer
  • Patent number: 7138543
    Abstract: The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: November 21, 2006
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Doris Stoermer, Dilrukshi Vitharana
  • Patent number: 7125907
    Abstract: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-? activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: October 24, 2006
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Takashi Tsukamoto
  • Patent number: 7101568
    Abstract: A biodegradable polymer composition comprising: (a) a poly(phosphoester) biodegradable polymer and (b) at least one antineoplastic agent in an amount effective to inhibit the growth of a solid tumor, which is suitable for intratumoral administration to treat a mammal having a solid tumor.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: September 5, 2006
    Assignee: Guilford Pharmaceuticals, Inc.
    Inventors: Wenbin Dang, Robert Garver, Jr.
  • Publication number: 20060003987
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: August 30, 2005
    Publication date: January 5, 2006
    Applicant: Guilford Pharmaceuticals, Inc.
    Inventors: Dana Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang
  • Publication number: 20050238616
    Abstract: The present invension relates to compositions of a biocompatible polymer and a antineoplastic agent for treating central nervous system neoplasms, and methods of using and making the same. In certain embodiments, the polymer contains phosphorous linkages. In other embodiments, the antineoplastic agent is an antineoplastic taxane. In still other embodiments, the subject methods of treatment use electromagnetic radiation.
    Type: Application
    Filed: January 9, 2003
    Publication date: October 27, 2005
    Applicant: Guilford Pharmaceuticals, Inc.
    Inventors: Wenbin Dang, Dana Hilt, William Vincek
  • Publication number: 20050182236
    Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 18, 2005
    Applicant: Guilford Pharmaceuticals, Inc.
    Inventors: Keith Branham, Mahesh Chaubal, James English, Donna Hall, Zhong Zhao
  • Publication number: 20050148575
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: February 28, 2005
    Publication date: July 7, 2005
    Applicant: Guilford Pharmaceuticals Inc.
    Inventors: Dana Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang
  • Patent number: 6887996
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: May 3, 2005
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Dana V. Ferraris, Jia-He Li, Vincent J. Kalish, Jie Zhang
  • Patent number: 6884907
    Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: April 26, 2005
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Pavel Majer, Bunda Hin, Weizheng Xu, Qun Liu, Doris Stoermer
  • Publication number: 20050074470
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: February 6, 2004
    Publication date: April 7, 2005
    Applicant: Guilford Pharmaceuticals, Inc.
    Inventors: Jia-He Li, Jie Zhang
  • Patent number: 6852750
    Abstract: New benzenedicarboxylic acid derivative compounds; pharmaceutical compositions, diagnostic methods, and diagnostic kits that include those compounds; and methods of using those compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, and glaucoma.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: February 8, 2005
    Assignee: Guilford Pharmaceuticals, Inc.
    Inventors: Paul F. Jackson, Takashi Tsukamoto, Barbara S. Slusher, Eric Wang
  • Patent number: 6812364
    Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&bgr; activity, inhibiting angiogenesis, and treating glutamate abnormalities, diabetic neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: November 2, 2004
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Pavel Majer, Doris Stoermer, Barbara S. Slusher
  • Patent number: 6806261
    Abstract: The present invention relates to methods for regulating the release of TGF-&bgr; from living cells in vitro or in vivo, comprising bringing the cells into contact with an effective amount of a NAALADase inhibitor. Such methods are believed to be useful for affecting neuroregeneration, cell proliferation, cell differentiation, extracellular matrix formation, myelination, inflammation, immune function, liver function, pancreatic function, angiogenesis, or wound healing; and/or for preventing or treating diabetes.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: October 19, 2004
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Xi-Chun May Lu, Krystyna Wozniak
  • Publication number: 20040204340
    Abstract: This invention relates to neurotrophic low molecular weight, small molecule peptidic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.
    Type: Application
    Filed: April 11, 2003
    Publication date: October 14, 2004
    Applicant: Guilford Pharmaceuticals, Inc.
    Inventors: Gregory S. Hamilton, Ling Wei, Joseph P. Steiner
  • Publication number: 20040198824
    Abstract: The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&bgr; activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.
    Type: Application
    Filed: April 7, 2004
    Publication date: October 7, 2004
    Applicant: Guilford Pharmaceuticals Inc.
    Inventors: Takashi Tsukamoto, Doris Stoermer, Dilrukshi Vitharana
  • Patent number: 6800672
    Abstract: Biodegradable, flowable or flexible polymer compositions are described comprising a polymer having the recurring monomeric units shown in formula I: wherein: each of R and R′ is independently straight or branched alkylene, either unsubstituted or substituted with one or more non-interfering substituents; L is a divalent cycloaliphatic group; R″ is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy; and n is 5 to 1,000, wherein said biodegradable polymer is biocompatible before and upon biodegradation. In one embodiment, one or more of R, R′ or R″ is a biologically active substance. Amorphous compositions containing a biologically active substance, in addition to the polymer, and methods for controllably releasing biologically active substances using the compositions, are also described.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: October 5, 2004
    Assignees: Guilford Pharmaceuticals, Inc., Johns Hopkins University School of Medicine
    Inventors: Wenbin Dang, Irina Kadiyala, Zhong Zhao, James P. English, Hai-quan Mao, Kam W. Leong
  • Publication number: 20040186081
    Abstract: The present invention relates to pharmaceutical compositions and methods for treating opioid tolerance using NAALADase inhibitors.
    Type: Application
    Filed: March 3, 2004
    Publication date: September 23, 2004
    Applicant: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Krystyna Wozniak